Safety, Tolerability, and Preliminary Efficacy Study of ALS-357 in Patients With Cutaneous Metastatic Melanoma

You may be eligible if

• Study Participants must be 18 years or older.
• Study Participants must have 2 sites of cutaneous metastatic melanoma that can not be removed with surgery.
• Study Participants may have been previously treated with chemotherapy or immunotherapy but not with in 4 weeks of first dose of study treatment.